Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

NHS backs Chiesi UK's delayed-release mercaptamine for cystinosis, expanding twice-daily treatment options
Small molecule, rare disease, regulatory, operational - Read more

Gilead Sciences exercises option to license MacroGenics' preclinical bispecific program, triggering $10M milestone payment
Licensing deal, oncology, bispecific antibody, milestone payments, royalties - Read more

Gan & Lee Pharmaceuticals, Menarini license Bofanglutide for obesity in Europe, €62M ($71.6M) upfront, €726M ($831.4M) total
Licensing deal, obesity, small molecule, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Stablepharma's SPVX02 tetanus-diphtheria vaccine shows promising Ph1 results without refrigeration requirement
Vaccine, infectious disease, thermostable vaccine, tetanus-diphtheria, cold chain, global health access - Read more

Definium Therapeutics' DT120 (LSD) succeeds in Ph3 trial for generalized anxiety disorder
Small molecule, neurological, psychedelic, LSD, generalized anxiety disorder, major depressive disorder - Read more

Boulevard Bio launches with $65M funding to advance three B cell-targeting autoimmune therapies, including quarterly-dosed IgA nephropathy drug BLVD101
Autoimmune, B cell biology, antibody, rare disease, clinical-stage - Read more

BridgeBio's Attruby hits $222M quarterly sales, nearing blockbuster status as ATTR stabilizer-first market emerges
Small molecule, cardiovascular, competitive, revenue impact - Read more

K2 Therapeutics raises $50M seed financing, in-licensing global first-in-class drug candidates
Oncology, antibody-drug conjugate, cell therapy, preclinical, in-licensing - Read more

Apollomics plans $10M private placement to fund oncology drug candidate development
Oncology, clinical-stage, small molecule, biopharmaceutical - Read more

Silence Therapeutics prices upsized $175M public offering, advancing siRNA therapies
Clinical-stage, siRNA, RNA interference, biotechnology - Read more

InduPro raises $77M Series B, backed by Sanofi and Lilly, funding cancer pipeline advancement
Oncology, induced proximity, bispecific antibody, platform technology, autoimmune, clinical-stage - Read more

Lentitek secures £725K ($837K) equity investment to accelerate cell & gene therapy commercialization
Cell & gene therapy, CAR-T, manufacturing, platform technology - Read more

Amgen to open Science and Innovation Center in Hyderabad's Genome Valley by 2027
R&D expansion, drug discovery, operational, strategic - Read more

WuXi AppTec wins preliminary injunction, temporarily blocking DOD's Chinese military company designation
Contract manufacturing, biosecurity, regulatory, operational, competitive - Read more

MHRA reaffirms childhood vaccine safety amid Trump's U.S. immunization schedule changes
Vaccine, infectious disease, public health, safety - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Eli Lilly files six lawsuits cracking down on black market illegal sales of obesity candidate retatrutide
Small molecule, obesity, competitive, operational - Read more

AbbVie, Bristol Myers Squibb, and Novartis sue Illinois over law protecting 340B contract-pharmacy arrangements
340B pricing, pharmaceutical policy, regulatory, operational, competitive - Read more

Aardvark Therapeutics scraps phase 3 trials, cuts workforce while awaiting next steps for stalled pipeline
Small molecule, rare disease, operational, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here